October 2, 2020 -- The U.S. Food and Drug Administration (FDA) has awarded Beckman Coulter emergency use authorization (EUA) for its Access Interleukin-6 (IL-6) assay. The automated immunoassay is designed to detect IL-6 levels in serum and plasma.
The assay can be used to identify a severe inflammatory response and determine the risk of mechanical ventilation intubation in COVID-19 patients. Being able to determine this risk ensures that only patients who really need the ventilator are placed on it.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current